



LUND UNIVERSITY

Protamine dosage effects on complement activation and sonoclot coagulation analysis after cardiac surgery

Schaub, Christian; Thomas, Owain; Åkervall Fridh, L; Schött, Ulf

Published in:
Cardiovascular System

DOI:
[10.7243/2052-4358-1-1](https://doi.org/10.7243/2052-4358-1-1)

2013

[Link to publication](#)

Citation for published version (APA):
Schaub, C., Thomas, O., Åkervall Fridh, L., & Schött, U. (2013). Protamine dosage effects on complement activation and sonoclot coagulation analysis after cardiac surgery. *Cardiovascular System*, (1).
<https://doi.org/10.7243/2052-4358-1-1>

Total number of authors:
4

General rights

Unless other specific re-use rights are stated the following general rights apply:
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117
221 00 Lund
+46 46-222 00 00



Protamine dosage effects on complement activation and sonoclot coagulation analysis after cardiac surgery

Christian Schaub¹, Thomas OD², Åkervall Fridh L³ and Ulf Schött^{4*}

*Correspondence: ulf.schott@skane.se

¹University hospital Giessen und Marburg and Erasmus Programme, Germany.

²Lund University and Skane University Hospital Department of Anaesthesiology and Intensive Care, S-22185, Lund, Sweden.

³Örebro University Hospital, Department of Cardiothoracic Anaesthesiology and Intensive Care S-701 85 Örebro, Sweden.

⁴Lund University and Skane University Hospital Department of Anaesthesiology and Intensive Care, S-22185, Lund, Sweden.

Abstract

Background: An optimal dosage and infusion regime for protamine reversal of heparin after cardiopulmonary bypass is important.

Methods: Protamine dosages of either 2mg/kg or 4mg/kg bodyweight were compared in 40 patients after first time coronary arterial bypass grafting. Protamine was infused with a syringe driver over 20 minutes. Arterial blood sampling was performed prior to and during surgery, before and at 0.3, 0.6, 1, 3, 6 and 25h after the protamine infusion. C3a-desArg and C4a-desArg were analysed by radioimmunoassay. Coagulation was assayed with Sonoclot and activated clotting time.

Results: Significantly higher inter-group plasma levels of C3a-desArg were seen with the greater protamine dose from 0.3-0.6h, but none for C4a-desArg. Sonoclot parameters and leucocyte count differed significantly between the groups up to 6h, indicating hypercoagulability with the higher protamine dose. Significantly longer ACT in the low protamine dosage group indicated unblocked heparin with nonsignificant increased drainage bleeding and transfusions. There were no signs of allergic or anaphylactic reactions in any of the groups.

Conclusion: Keeping the protamine dose low, minimizes complement activation with less viscoelastic signs of hypercoagulability. However there is an increased risk for drainage bleeding and unnecessary transfusion if heparin is not fully reversed with protamine post cardiopulmonary bypass. The present study was underpowered to detect significant differences in bleeding.

Keywords: Protamine, complement activation, C3a, sonoclot, cardiopulmonary bypass surgery

Introduction

Several adverse reactions may occur after intravenous protamine administration for rapid reversal of heparin anticoagulation [1]. Respiratory (wheezing), cardiovascular (pulmonary vasoconstriction, pulmonary artery hypertension, hypotension, decreased cardiac contractility, bradycardia, cardiac arrest and ventricular fibrillation), skin (flushing, urticaria, and angioedema) and hematological (bleeding) have been reported [1]. Protamine reactions are both immunologically mediated and a result of direct toxicity [1,2].

Contrary to cardiopulmonary bypass (CPB) which activates the alternative complement pathway, especially through surface contact in the oxygenator [3-5], protamine activates the complement system through the classical pathway. After cardiopulmonary bypass (CPB), administering protamine in a higher dose given over a shorter time (<5 minutes) increases the risk for pulmonary and hemodynamic adverse reactions [6].

The optimal dose of protamine for hemostasis has achieved great interest: an excessive dose of protamine after CPB can prolong ACT and decrease platelet function [7], but it has not been confirmed that this leads to increased postoperative bleeding [8,9]. Khan et al., [8] demonstrated a hypocoagulable thrombelastography pattern when excess protamine was added

in-vitro to blood samples from heparinized patients undergoing cardiac surgery with CPB, but did not investigate whether this had any significance for actual postoperative bleeding. Free protamine together with heparin in plasma seems to affect platelet function less than free protamine without heparin [10]. Thromboelastography has the best predictability/accuracy so far amongst routine tests for post-CPB bleeding [11,12]. The effects of different protamine dosages on complement activation and viscoelastic coagulation tests / postoperative bleeding, have not been studied.

The aim of this prospective, randomized and open study was to evaluate a reduced dose of protamine, infused over 20 minutes with a syringe driver on complement activation, Sonoclot coagulation analysis and clinical bleeding parameters in patients undergoing CABG. Our hypothesis was that a reduced protamine dose would decrease complement activation without increased postoperative drainage bleeding.

Material and methods

The study was prospective, open study, with no withdrawals or drop-outs. Following a pilot study on different levels of complement activation after cardiac surgery with two different dose regimes of protamine, whose patients are not included

in this study, we anticipated a sample size of 40 patients to reach a power of >0.80 in a study with 2 different protamine dosages.

Forty patients with stable angina pectoris, scheduled for primary elective CABG surgery were prospectively randomized into two groups, 20 patients in each group. Patients were eligible for inclusion if they were planned for elective CABG for stable angina and had given written consent. Patients with known coagulation or bleeding disorders were excluded, as were patients participating in other clinical studies. An informed and written consent was obtained preoperatively from each patient for the use of their personal data for scientific purposes according to the Helsinki Declaration. The study was approved by the local ethics committee (Örebro University Hospital) and conducted at that same hospital.

Patients received one of two schematic protamine chloride (porcine mucine heparin, Leo Pharma, Sweden) dosages of either 2mg/kg or 4mg/kg bodyweight (BW). The 4mg/kg BW protamine dose corresponds to the commonly recommended protamine dose for heparin reversal after CPB/CABG of 1mg/100 IU heparin. A study nurse broke the sequentially numbered opaque sealed randomization envelope for each patient at the time of the operation. Infusion was achieved using a syringe driver over 20 minutes after the end of CPB. The study nurse also collected blood samples at the scheduled time intervals. Additional protamine was permitted in dosages of 25 mg first 1h after the protamine infusion, and was indicated by increased drainage bleeding (>100 ml/h during each of the following 3 hours and >50 ml/h thereafter).

Hemochron® JR-ACT (International Technidyne Corp, NJ, USA) was measured before and after additional protamine. Postoperative drainage blood loss was evaluated up to 25 h after the protamine infusion. Blood was autotransfused from the oxygenator reservoir up to 5 h after the protamine infusion.

The safety monitoring consisted of registration of heart rate, blood pressure, respiratory pressures, respiratory volume/pressure loops/dynamic compliance and adverse events (with special consideration of postoperative bleeding).

An initial full dose of heparin (porcine-based standard heparin, Leo, Sweden), 300 IU/kg body weight was given to all patients. If insufficient heparinization with ACT <480 seconds was not achieved, extra heparin was administered before cardiac cannulation in repeated doses of 5000 IU up to 500 IU/kg BW. ACT was maintained >480 s during CPB according to recommendations from the manufacturer of the oxygenator. CPB was performed with a heart-lung machine (Stöckert SIII, Germany), the membrane oxygenator (D903 Avant, Dideco, Italy) being primed with 2 L of crystalloid. 10 000 IE heparin was added to the pump prime of the heart-lung machine. CPB was conducted with moderate hypothermia of 30–32°C (rectal temperature) and a flow rate of 2.4 L/min/m². Pulsative blood flow was not maintained during the CPB period.

The patients received standard anaesthesia with fentanyl, thiopentone, isoflourane and pancuronium, and were monitored

using arterial and central venous catheters and respiration loops (AS3, Datex, Finland).

Blood was sampled from indwelling arterial catheters with vacutainer technique (Venoject, UK) into EDTA glass test tubes containing 0.38 M EDTA-K3 (Becton Dickinson, USA). Blood was sampled prior to induction, after sternotomy, after CPB-start, before protamine, 0.3 hours (h), 1h, 3h, 6h and 24h after protamine infusion. Activated complement, C3a-desArg and C4a-desArg were analysed from plasma frozen to -70 C using radioimmunoassay methods from Kabi UpJohn Diagnostics (Kabi Upjohn Company, Kalamazoo, USA) as has been described in a previous study [13].

Arterial blood gas analysis (Radiometer, Denmark) also included hemoglobin (Hb). Routine laboratory analyses included platelet (plc) and leucocyte count (LC), activated partial thromboplastin time (aPTT), fibrinogen and antithrombin and were performed preoperatively, 2 h after and 25 h after protamine.

A Sonoclot coagulation analyser (Sienco Inc, Boulder, CO, USA) was used for viscoelastic native whole blood coagulation analyses as described in a recent study [14] with SonACT celite activated cuvettes – ACT, clot rate (CR) and time to peak (ttP) were registered.

Statistical analyses with T-tests were performed to determine whether there were differences between groups with respect to demographic and bleeding data. Individual changes from the starting values for arterial blood pressures, CVP, peak respiratory pressures, laboratory and Sonoclot coagulation data were analyzed by repeated ANOVAs with the factors time, treatment and patient within treatment. The first two factors were considered as fixed factors and the last (patient within treatment) as a random factor. Significant interactions were tested by Tukey's test. Residuals were examined and transformations were made if necessary. Bonferoni corrections were made for multiple comparisons. A statistical difference with a $p<0.05$ was regarded as significant (marked as x for intergroup comparisons in Figures and Table).

Results

All laboratory and bleeding data were normal distributed according to histogram displays and kurtosis and skewness testing with SPSS software, and are expressed as mean \pm SEM (standard error of mean). There were no significant differences ($p>0.05$) in demographic data (sex, age, body mass index (BMI)), heparin dosages, extracorporeal circulation (ECC), time aortic clamping-time, additive protamine dosages, antithrombin, fibrinogen, aPTT, total blood loss and blood transfusion between the groups (Table 1, mean \pm standard error of mean (SEM)). Hourly drainage bleeding and autotransfusion up to 5h post protamine are shown in Figure 1 (mean \pm SEM), with no significant statistical differences ($p>0.05$). Mean \pm SEM changes in Hb, plc and LC are shown in Figure 2. There were only significant statistical differences between the groups in LC at 3-5h.

Table 1. Demographic, mean (sem) transfusion, anticoagulation, surgical and laboratory data from the two groups (mean +SEM). There were no significant differences between the groups.

Group	2 mg/kg protamine (n=20)	4mg/kg protamine (n=20)
Gender (male/female)	15/5	16/4
Age	60(5)	61(5)
BMI	27.65 (0.8)	26 (0.8)
Initial heparin dose (ml)	4.8 (0.2)	4.8 (0.2)
Extra heparin dose (ml)	n=6 2.3 (0.3)	n=7 1.8 (0.2)
Protamine dose/IU heparin	0,54 mg/100 IU	0,96 mg/100 IU
ECC time (min)	110(5)	96(8)
Aortic clamping time (min)	58(4)	55(5)
ERC transfusion during surgery (units)	0.6 (0.2)	0.3 (0.1)
ERC transfusion after surgery (units)	0.9(0.2)	0.5 (0.2)
Total bleeding (ml)	999(53)	887(75)
Antithrombin preop-25h	0.95(0.02)- 0.7(0.07)	1.0(0.03)- 0.7(0.05)
aPTT (s) preop-6h-25h	27-34-28	27-30-28
Fibrinogen (gram/L) preop-6h-25h	3.6-2.3-3.2	3.9-2.9-3.7





Figure 1a+b. Hourly drainage bleeding and autotransfusion. There were no significant intergroup differences up to 5 hours postoperatively (mean +SEM).




Figure 2a+b+c. Changes in hemoglobin (Hb), platelet (plc) and leucocyte count (LC)(mean +SEM). LC was significantly higher (*) at 3-5 hours in the group receiving 4mg/kgprotamine. There were no significant intergroup differences in Hb or plc between the groups.

Significantly higher ($p < 0.05$) plasma levels of C3a-desArg were seen with the higher protamine dose (4mg/kg BW) up to 0.6h post-protamine compared to the 2mg/kg BW dose (Figure 3, mean+SEM). C3a-desArg increased significantly from before protamine up to 3h post-protamine as compared




Figure 3. C3a-desarg changes in the two protamine dosage groups (mean +SEM). C3a was significantly higher (*) at 0,3 and 0,6 h in the group receiving 4mg/kg protamine.




Figure 4. C4a-des-arg changes in the two protamine dosage groups (mean +SEM). There were no significant intergroup differences.

to preoperative values in both groups (Figure 3) C4a did not significantly differ between the groups, but increased significantly compared to preoperative baseline plasma levels in both groups from 3h and onwards (Figure 4, mean+SEM).

Sonoclot parameters ACT, clot rate (CR) and time to peak (ttP) significantly differed between the groups ($p < 0.01-0.001$) after protamine up to 4h (ACT/CR) and 5h (ttP) (Figure 5, mean+SEM). Intragroup comparison indicated a postoperative hypercoagulability in the 4mg/kg BW protamine group for ACT, CR and ttP. Sonoclot-ACT correlated with Hemochron-ACT with






Figure 5a+b+c. Sonoclot-ACT, -CR and -time to peak (ttP) changes in the two protamine dosage groups (mean +SEM). ACT was significantly longer (*) at 2-4 h in the group receiving 2mg/kg protamine. Sonoclot-CR was significantly higher (*) and ttP shorter (*) in the group receiving 4mg/kg protamine.

a significant ($p < 0.001$) regression factor 0.92.

Discussion

With the introduction of radioimmunosassays (RIA) in the early 1970's, complement activation during cardiopulmonary bypass could be detected at low levels [7]. RIA-tests for C3a, C4a and C5a were made commercially available, and increased plasma levels of these so called anaphylatoxins could be detected in a multitude of clinical and experimental settings. Complement may be activated by either the classical (C4a, C3a) or alternate pathway (C3a) during CPB. The systemic effects of the anaphylatoxins are normally well regulated by the activity of carboxypeptidase and by the rapid influx to sites of complement activation of neutrophils and monocytes, whose receptors act as a sink for C5a, which is internalized and inactivated by proteolysis [15]. Although C5a is the strong estaphylatoxin and chemoattractant, increased plasma levels have seldom been detected during CPB due to this internalization [16]. All of these peptides have anaphylatoxic activity, they cause smooth muscle contraction and degranulation of mast cells and basophils, with consequent release of histamine and other vasoactive substances that induce capillary leakage.

C5a is the most potent of these anaphylatoxins. C5a and C3a also have immunoregulatory effects on T cell function, either stimulating or inhibiting aspects of cell-mediated immunity [17]. Due to a 100% cross reactivity between C3a, C4a and C5a and their respective desarginated inactive degradation products C3a-desArg, C4a-desArg and C5a-desArg (C5a-desArg retains 10% anaphylatoxic activity) the pathophysiological meaning of the increased plasma levels of the anaphylatoxins have not always been clear [18]. Species differences in the complement system and its interaction with neutrophils/monocytes/macrophages and their release reactions of intracellular enzymes, free radicals, leukotrienes and thromboxanes have been clarified [19].

With introduction of new and more specific monoclonal, neoantigenic antibody assays for complement activation/complement split products (ELISA), terminal complement complex (TCC), complement receptors and introduction of antibody-designed antagonists of different activation products and receptors, a better understanding of the complement system and its pathophysiology has evolved [20,21].

There were no differences in C3a and C4a between the groups intraoperatively prior to the protamine infusion. A significant increase in C3a and for C4a (Figures 3 and 4) could be seen as compared to preoperative values. C3a usually starts to increase shortly after the onset of CPB with a continuing rise during the bypass. Complement activation during cardiac surgery has also been associated with heparin, antibiotics, blood products and volume expanders during cardiopulmonary bypass [22]. Membrane oxygenators appear to diminish the degree of complement activation [22]. The introduction of heparin coated ECC systems has also decreased

complement activation during CPB [3].

Significantly higher plasma levels of C3a-desArg were seen with the 4mg/kg BW protamine dosage up to 0.6h post-protamine compared to the 2mg/kg BW dosage (Figure 3). Protamine can decrease carboxypeptidase (CPN) and thereby enhance complement activation effects². This has been opposed by Rabito et al., [23] who only found the decrease in CPN during CPB to be caused by dilution and not to changes in CPN synthesis, catabolism or protamine. Cardiac, pulmonary, renal and hematological dysfunction after CBP, longer elapsed times of bypass and younger age at operation have been correlated to increased levels of C3a/C3a-desArg [24].

No such correlations were found in this study. Furthermore, no deterioration in hemodynamics or pulmonary function could be correlated to the higher complement activation in patients with the 4mg/kg protamine dose regime. Current CBP pathophysiology focuses on other immunologic markers than complement and more sophisticated tests of organ dysfunction probably need to be used instead of the routine hemodynamic monitoring, Servo 300C-derived respiratory parameters and blood gas analyses [25].

A rapid protamine injection/infusion can induce hypotension. This rate or free-concentration-dependent hypotension may result from several causes. Proposed explanations include stimulation of endothelium-derived relaxing factor release, inhibition of plasma carboxypeptidase N, inactivation of various vasoactive peptides, and a non-immunologic release of histamine from mast cells. Histamine can be released by protamine from isolated human cutaneous mast cells at high concentrations but not from lung mast cells. Some protamine reactions may be associated with complement activation via the classical pathway, either through protamine-heparin complexes or through protamine and anti-IgG-antibody interaction. The generation of anaphylatoxins may induce mediator release from mast cells and can also stimulate the generation of new mediators, such as thromboxane A2 from membrane phospholipids of activated leucocytes [1,2,5,16,18].

Other reactions probably represent classical immunoglobulin E (IgE)-mediated allergy and present as classical anaphylactic reactions with rash, urticaria, bronchospasm, and systemic vasodilation. A pronounced increase in pulmonary artery pressure from pulmonary vasoconstriction with secondary right heart failure is seen in some patients. This reaction is probably mediated by release of thromboxane A2 into the plasma, since its metabolite, thromboxane B2 concentration correlates to the degree of vasoconstriction [1].

Prior exposure to protamine from protamine containing insulin (now uncommon) increases the risk of severe protamine reaction during CPB [1]. Only one patient in our study had insulin treated diabetes and there were no signs of anaphylactic reaction in this patient nor exaggerate complement activation. None of our patients had received heparin before.

The presence of cross-reacting antibodies in patients with

fish allergies or previous vasectomy has also been implicated as a risk factor for severe protamine reaction, but the evidence is limited to case reports and has not been verified in a series of such patients [1]. None of our patients had fish allergy or had undergone vasectomy. Diabetes, valvular surgery, and preexisting pulmonary hypertension have been suggested to be risk factors for pulmonary vasoconstriction but the data does not support these suggestions [2]. Only one of our patients was diabetic (Table 1), and no pulmonary reaction or difference in complement activation could be detected. Although the infusion rate may not affect IgG or IgE-mediated anaphylactic reactions, it attenuates responses that may depend on the concentration of free protamine and circulating heparin-protamine complexes [1]. A slow infusion rate is always advisable [6].

Protamine excess may increase ACT, decrease platelet aggregation and worsen thrombin function *in vitro* [9]. The plasma level of free protamine required for these phenomena to reach clinical significance remains uncertain: one somewhat aged study suggests that large excesses of protamine are clinically insignificant [26] but only tests of plasma coagulation and not platelet function or bleeding outcomes were used. ACT is a non-specific test for detection of heparin rebound [9].

An intra-group hypercoagulable Sonoclot response was seen with the higher protamine dose in the present study with higher clot rate and stronger platelet function, but also as compared to preoperative baseline values. Increased platelet activity and high fibrin deposition rates in viscoelastic tests have been associated with venoarterial thrombosis, TIA/stroke, graft occlusion after aortofemoral-bypass surgery and in cancer [27,28]. Protamine infusion may both stimulate platelet-activating factor (PAF) biosynthesis by leukocytes in the lung and accelerate the disappearance of PAF in the arterial bed. An imbalance in such mechanisms may favour platelet aggregation, explaining stronger platelet activity as indicated by the shorter time to peak in the Sonoclot. Complement activation may play a role in this hypercoagulable response, due to its several bridges to the coagulation cascade [29]. Leucocyte count (LC) was higher after protamine in the 4 mg/kg BW protamine group (Figure 5) and this may also induce a hypercoagulable response.

The significantly prolonged ACT in both the Sonoclot and Hemochron (not shown) with the lower dose of protamine probably indicate unblocked heparin with inhibition of fibrin and platelets as indicated by the decrease in CR and prolongation of time to peak (Figure 5). The most commonly used protamine protocols determine the reversal dose of protamine based on the total dose of heparin given during bypass, using a reversal ratio of 1 to 1.5 mg protamine per 100 U heparin. These methods do not account for the elimination of heparin during bypass and may result in substantial overdose of protamine. The protamine doses calculated from the heparin dose-ACT response curve, heparin level measurement (heparin-protamine titration - Hemotec®),

or protamine dose-ACT response *in vitro* (Hemochron) all result in lower doses [9] as the more advanced Hepcon HMS. Reduced-dose protamine protocols should be used since they have been associated with less bleeding [9].

Additional small doses of protamine may be warranted after reinfusion of blood remaining in the CPB circuit after decannulation. There was no difference in extra doses of protamine in our two groups (Table 1). The completeness of the heparin reversal is assessed 5 to 10 minutes after the end of infusion by measuring ACT. If the ACT has returned to baseline, heparin level measurement can also be helpful in ascertaining whether the dose of protamine has been sufficient [9]. ACT will be consistently prolonged only after heparin concentrations exceeding 0.1 U/ml. A normal ACT does not preclude the presence of a significant amount of heparin [9] since the reagent formulations being used are designed for high dose heparin management and are less responsive to residual levels of heparin. Heparinase coupled to ACT methodology seems to be a promising and practical way to uncover residual unneutralized heparin [9]. We did not give extra protamine during the first hour as we wanted to clearly separate the degree of complement activation in the two groups. ACT was higher and Sonoclot indicated unblocked heparin in the group receiving the lower dose of protamine. The transfusion of ERC, hourly drainage bleeding and autotransfusion were all higher in the low protamine dosage group – and would probably become significant with more study patients. Especially the almost 50% higher transfusion rate in the low protamine dosage group and this difference still being nonsignificant indicates that our study is underpowered.

Although initial neutralization of heparin with all of the previously described methods is adequate, small amounts of free heparin can be detected with chromogenic substrate assay or repeat protamine titration between 1 and 5 hours after neutralisation [9]. Heparin level measurement at the end of bypass may be the most practical of these protocols. In the absence of a heparin level measuring device, a dose of 1 mg protamine for each 100 U heparin given before CPB will almost invariably result in complete reversal of heparin [30].

There are several limitations of our study. First the power was calculated on protamine activation of C3a, and here we saw a significant dose response ($p < 0.05$), whereas none of the clinical parameters (hemodynamic, respiratory, bleeding and transfusion parameters) significantly differed. The study is surely underpowered for detecting anaphylactic reactions as they are infrequent, especially so - when the protamine is given slowly as in the present study. There is a trend for increased ERC transfusion, autotransfusion, drainage bleeding, lowered postoperative haemoglobin in the low protamine group and together with the longer ACTs this indicates unblocked heparin. With more patients we would probably have seen significant differences in these data. Alternatively if we had chosen to block prolonged ACTs (>140 s), drainage

bleeding, transfusion need would probably decrease in the low protamine group irrespective of the size of the study groups. Also we chose to nonblind the procedure, and this is a default in study design, possibly being outweighed by the same study nurse securing the protocol and sampling throughout the study.

In conclusion, keeping protamine dosages low will reduce complement activation. Sonoclot indicated a risk of immediate postoperative hypercoagulability with unnecessarily high protamine doses with clot structure parameters CR and tTP, whereas both standard and Sonoclot-ACTs indicated initial insufficient heparin reversal, with increased bleeding and transfusions. The impact on early graft occlusions should be further studied with viscoelastic tests balancing postoperative coagulation.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Schött planned the study (at the time of the study affiliated to Örebro University Hospital) and performed it together with Åkervall-Fridh. Medical student Schaub processed the draft together with Thomas and Schött. Thomas made the graphs and statistics.

Acknowledgement and funding

The study was funded by Örebro County Council and ALF – ISEK University in Lund.

Publication history

Received: 5-Feb-2013 Revised:12-Feb-2013

Re- Revised: 19-Feb-2013 Accepted: 21-Feb-2013

Published: 27-Feb-2013

References

1. Porsche R and Brenner ZR: **Allergy to protamine sulfate.** *Heart Lung* 1999, **28**:418-28. | [Article](#) | [PubMed](#)
2. Weiss ME and Adkinson NF, Jr.: **Allergy to protamine.** *Clin Rev Allergy* 1991, **9**:339-55. | [Article](#) | [PubMed](#)
3. Tagarakis GI and Tsilimingas NB: **Heparin-coated extracorporeal circulation systems in heart surgery.** *Recent Pat Cardiovasc Drug Discov* 2009, **4**:177-9. | [Article](#) | [PubMed](#)
4. Wendel HP and Ziemer G: **Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation.** *Eur J Cardiothorac Surg* 1999, **16**:342-50. | [Article](#) | [PubMed](#)
5. Svennevig JL, Geiran OR, Karlens H, Pedersen T, Mollnes TE, Kongsgard U and Froyssaker T: **Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits.** *J Thorac Cardiovasc Surg* 1993, **106**:466-72. | [Article](#) | [PubMed](#)
6. Dunning J, Versteegh M, Fabbri A, Pavie A, Kolh P, Lockowandt U and Nashef SA: **Guideline on antiplatelet and anticoagulation management in cardiac surgery.** *Eur J Cardiothorac Surg* 2008, **34**:73-92. | [Article](#) | [PubMed](#)
7. Knudsen F and Andersen LW: **Immunological aspects of cardiopulmonary bypass.** *J Cardiothorac Anesth* 1990, **4**:245-58. | [PubMed](#)
8. Khan NU, Wayne CK, Barker J and Strang T: **The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph.** *Eur J Anaesthesiol* 2010, **27**:624-7. | [Article](#) | [PubMed](#)
9. Despotis GJ, Gravlee G, Filos K and Levy J: **Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques.** *Anesthesiology* 1999, **91**:1122-51. | [Article](#) | [PubMed](#)
10. Carr ME Jr, Carr SL: **At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects.** *Thromb Res* 1994, **75**:617-30. | [Article](#)
11. Ganter MT and Hofer CK: **Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices.** *Anesth Analg* 2008, **106**:1366-75. | [Article](#) | [PubMed](#)
12. Forestier F, Belisle S, Contant C, Harel F, Janvier G and Hardy JF: **[Reproducibility and interchangeability of the Thromboelastograph, Sonoclot and Hemochron activated coagulation time in cardiac surgery].** *Can J Anaesth* 2001, **48**:902-10. | [Article](#) | [PubMed](#)
13. Norda R, Schott U, Berseus O, Akerblom O, Nilsson B, Ekdahl KN, Stegmayr BG and Knutson F: **Complement activation products in liquid stored plasma and C3a kinetics after transfusion of autologous plasma.** *Vox Sang* 2012, **102**:125-33. | [Article](#) | [PubMed](#)
14. Schott U, Nilsson LG, Broman M and Engstrom M: **Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.** *Perfusion* 2010, **25**:191-6. | [Article](#) | [PubMed](#)
15. Manthey HD, Woodruff TM, Taylor SM and Monk PN: **Complement component 5a (C5a).** *Int J Biochem Cell Biol* 2009, **41**:2114-7. | [Article](#) | [PubMed](#)
16. Bruins P, te Velthuis H, Eerenberg-Belmer AJ, Yazdanbakhsh AP, de Beaumont EM, Eijssman L, Trouwborst A and Hack CE: **Heparin-protamine complexes and C-reactive protein induce activation of the classical complement pathway: studies in patients undergoing cardiac surgery and in vitro.** *Thromb Haemost* 2000, **84**:237-43. | [Article](#) | [PubMed](#)
17. Sacks SH: **Complement fragments C3a and C5a: the salt and pepper of the immune response.** *Eur J Immunol* 2010, **40**:668-70. | [Article](#) | [PubMed](#)
18. Levy JH and Tanaka KA: **Inflammatory response to cardiopulmonary bypass.** *Ann Thorac Surg* 2003, **75**:S715-20. | [Article](#) | [PubMed](#)
19. Gillinov AM, Redmond JM, Winkelstein JA, Zehr KJ, Herskowitz A, Baumgartner WA and Cameron DE: **Complement and neutrophil activation during cardiopulmonary bypass: a study in the complement-deficient dog.** *Ann Thorac Surg* 1994, **57**:345-52. | [Article](#) | [PubMed](#)
20. Mollnes TE, Jokiranta TS, Truedsson L, Nilsson B, Rodriguez de Cordoba S and Kirschfink M: **Complement analysis in the 21st century.** *Mol Immunol* 2007, **44**:3838-49. | [Article](#) | [PubMed](#)
21. Oppermann M and Wurzner R: **Modern determination of complement activation.** *Semin Thromb Hemost* 2010, **36**:611-9. | [Article](#) | [PubMed](#)
22. Utley JR: **Pathophysiology of cardiopulmonary bypass: current issues.** *J Card Surg* 1990, **5**:177-89. | [PubMed](#)
23. Rabito SF, Anders R, Soden W and Skidgel RA: **Carboxypeptidase N concentration during cardiopulmonary bypass in humans.** *Can J Anaesth* 1992, **39**:54-9. | [Article](#) | [PubMed](#)
24. Kongsgaard UE, Smith-Erichsen N, Geiran O and Bjornskau L: **Duration of cardiopulmonary bypass compared with changes in the plasma protease systems.** *Scand J Thorac Cardiovasc Surg* 1991, **25**:223-6. | [Article](#) | [PubMed](#)
25. Gourlay T and Shedden L: **The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress.** *Perfusion* 2010, **25**:427-9; author reply 429-30. | [Article](#) | [PubMed](#)
26. Ellison N, Ominsky AJ and Wollman H: **Is protamine a clinically important anticoagulant? A negative answer.** *Anesthesiology* 1971, **35**:621-9. | [Article](#) | [PubMed](#)
27. Rafiq S, Johansson PI, Ostrowski SR, Stissing T and Steinbruchel DA: **Hypercoagulability in patients undergoing coronary artery bypass grafting: prevalence, patient characteristics and postoperative outcome.** *Eur J Cardiothorac Surg* 2012, **41**:550-5. | [Article](#) | [PubMed](#)
28. Akay OM, Ustuner Z, Canturk Z, Mutlu FS and Gulbas Z: **Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography.** *Med Oncol* 2009, **26**:358-64. | [Article](#) | [PubMed](#)
29. Osterud B, Olsen JO and Benjaminsen AW: **The role of complement in**

the induction of thromboplastin synthesis. *Haemostasis* 1984, **14**:386-92. | [Article](#) | [PubMed](#)

30. Hirsh J and Raschke R: **Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.** *Chest* 2004, **126**:188S-203S. | [Article](#) | [PubMed](#)

Citation:

Schaub C, Thomas O D, Åkervall Fridh L and Schött U:
**Protamine dosage effects on complement activation
and sonoclot coagulation analysis after cardiac surgery.**
Cardiovascular System 2013, **1**:1.
<http://dx.doi.org/10.7243/2052-4358-1-1>